Prev:Next:

Doctoral supervisor, Chief and chief physician of the department of medical oncology, Beijing Chest Hospital, Capital Medical University.

Committeeman of Oncology branch, Chinese Medical Association (CMA).

Committeeman of Clinical Cancer Chemotherapy Committee, China Anti-Cancer Association.

Executive committeeman of Chinese Geriatric Oncology Society (CGOS)

Vice chairman of Lung Cancer sub-Committee, CGOS.

Executive director of Beijing Anti-Cancer Association

Deputy director of Lung Cancer Center, Capital Medical University.

Study at MD Aderson Cancer Center as a visiting-scholar in 2006.

Won the first prize of National Science and Technology Progress Prize for the year of 2015 as a main participant of the project “Development, research, industrialization，popularization and application of the small molecule targeted anti-cancer drug icotinib hydrochloride”.

Directs a study As PI of a domestic multicenter, randomized, prospective clinical trail conducted in 20 hospitals “High-dose icotinib in advanced non-small cell lung cancer with EGFR 21L858R mutation: the randomized, open-label INCREASE study”. Participated in many well-known international multicenter clinical trials.

Editorial board member of a number of journals including Chinese Journal of Oncolocy, Chinese Journal of Lung Cancer, National Medical Journal of China, Chinese Journal of Clinicians, Chinese Journal of General Practitioners, The Journal of Chinese Oncology and Journal of Thoracic Oncology, et. al.